Browse > Article

Enhanced Virus Safety of a Solvent/Detergent-Treated Anti-hemophilic Factor IX Concentrate by Dry-Heat Treatment  

Shin Jeong-Sup (Green Cross Corp., Department of Molecular Science and Technology, College of Engineering, Ajou University)
Choi Yong-Woon (Green Cross Corp.)
Sung Hark-Mo (Green Cross Corp.)
Ryu Yeon-Woo (Department of Molecular Science and Technology, College of Engineering, Ajou University)
Kim In-Seop (Department of Biological Sciences, College of Natural Sciences, Hannam University)
Publication Information
Biotechnology and Bioprocess Engineering:BBE / v.11, no.1, 2006 , pp. 19-25 More about this Journal
Abstract
With particular regards to the hepatitis A virus (HAV), a terminal dry-heat treatment ($100^{\circ}C$ for 30 min) process, following lyophilization, was developed to improve the virus safety of a solvent/detergent-treated antihemophilic factor IX concentrate. The loss of factor IX activity during dry-heat treatment was of about 3%, as estimated by a clotting assay. No substantial changes were observed in the physical and biochemical characteristics of the dry-heat-treated factor IX compared with those of the factor IX before dry-heat treatment. The dry-heat-treated factor IX was stable for up to 24 months at $4^{\circ}C$, The dry-heat treatment after lyophilization was an effective process for inactivating viruses. The HAV and murine encephalomyocarditis virus (EMCV) were completely inactivated to below detectable levels within 10 min of the dry-heat treatment. Porcine parvovirus (PPV) and bovine herpes virus (BHV) were potentially sensitive to the treatment. The log reduction factors achieved during lyophilization and dry-heat treatment were ${\ge}5.60$ for HAV, ${\ge}6.08$ for EMCV, 2.64 for PPV, and 3.59 for BHV. These results indicate that dry-heat treatment improves the virus safety of factor IX concentrates, without destroying the activity. Moreover, the treatment represents an effective measure for the inactivation of non-lipid enveloped viruses, in particular HAV, which is resistant to solvent/detergent treatment.
Keywords
antihemophilic factor IX; dry-heat treatment; hepatitis A virus; virus inactivation;
Citations & Related Records

Times Cited By Web Of Science : 5  (Related Records In Web of Science)
Times Cited By SCOPUS : 7
연도 인용수 순위
1 O'Connell, N. M. (2003) Factor XI deficiency-from molecular genetics to clinical management. Blood Coagul. Fibrinolysis 14 Suppl 1: S59-S64   DOI
2 Tabor, E. (1999) The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 39: 1160-1168   DOI   ScienceOn
3 Morgenthaler, J. J. (2000) New development in plasma fractionation and virus inactivation. Vox Sang. 78 Suppl 2: 217-221   DOI
4 Laub, R. and P. Strengers (2002) Parvovirus and blood products. Pathol. Biol. (Paris) 50: 339-348   DOI
5 Kim, I. S., Y. W. Choi, S. R. Lee, and H. M. Sung (2004) Cold ethanol fractionation and heat inactivation of hepatitis A virus during manufacture of albumin from human plasma. Biotechnol. Bioprocess Eng. 9: 57-60
6 Arrighi, S., R. Rossi, M. G. Borri, V. Lesnikov, M. Lesnikova, E. Franco, M. Divizia, M. E. de Santis, and E. Bucci (1995) 'In vitro' and in animal model studies on a double virus-inactivation factor VIII concentrate. Thromb. Haemost. 74: 868-873
7 Kim, I. S., Y. W. Choi, S. R. Lee, Y. Kang, K. M. Lee, D. H. Park, H. S. Woo, and S. Lee (2002) Removal and inactivation of hepatitis A virus during manufacture of urokinase from human urine. Biotechnol. Bioprocess Eng. 7: 340-346   DOI   ScienceOn
8 Karber, J. (1931) Beitrag zur kollectiven Behandlung pharmakologische Reihenversuche. Arch. Exp. Pathol. Pharmakol. 162: 480-483   DOI
9 Murgatroyd, K. (1997) The freeze drying process. pp. 1- 58. In: P. Cameron (eds.). Good Pharmaceutical Freeze- Drying Practice. Interpharm Press, Buffalo Grove, IL, USA
10 Mosley, J. W. and J. Rakela (1999) Foundling viruses and transfusion medicine. Transfusion 39: 1041-1044   DOI   ScienceOn
11 Lawlor, E., S. Graham, E. Davidson, P. L. Yap, C. Cunningham, H. Daly, and I. J. Temperley (1996) Hepatitis A transmission by factor IX concentrates. Vox Sang. 71: 126-128   DOI   ScienceOn
12 Kim, I. S., Y. W. Choi, and S. R. Lee (2004) Optimization and validation of a virus filtration process for efficient removal of viruses from urokinase solution prepared from human urine. J. Microbiol. Biotechnol. 14: 140-147
13 Burnouf, T. and M. Radosevich (2000) Reducing the risk of infection from plasma products: specific preventative strategies. Blood Rev. 14: 94-110   DOI   ScienceOn
14 Chudy, M., I. Budek, B. Keller-Stanislawski, K. A. McCaustland, S. Neidhold, B. H. Robertson, C. M. Nubling, R. Seitz, and J. Lower (1999) A new cluster of hepatitis A infection in hemophiliacs traced to a contaminated plasma pool. J. Med. Virol. 57: 91-99   DOI   ScienceOn
15 Robinson, S. M., H. Schwinn, and A. Smith (1992) Clotting factors and hepatitis A. Lancet 340: 1465   DOI   ScienceOn
16 Dichtelmuller, H., D. Rudnick, B. Breuer, R. Kotitschke, M. Kloft, A. Darling, E. Watson, B. Flehmig, S. Lawson, and G. Frosner (1996) Improvement of virus safety of a S/D-treated factor VIII concentrate by additional dry heat treatment at 100$^{\circ}C$. Biologicals 24: 125-130   DOI   ScienceOn
17 Andrewes, C. (1989) Andrewes' Viruses of Vertebrates. pp. 120-145. Balliere Tindal, London, UK
18 Powell J. S., M. Bush, J. Harrison, C. Abildgaard, E. Vosburgh, A. R. Thompson, and D. Hurst (2000) Safety and efficacy of solvent/detergent-treated antihaemophilic factor with an added 80$^{\circ}C$ terminal dry heat treatment in patients with haemophilia A. Haemophilia 6: 140-149   DOI   ScienceOn
19 Kim, I. S. (2003) Comparative inactivation of Hepatitis A virus and Murine Encephalomyocarditis virus to various inactivation processes. Kor. J. Microbiol. 39: 242-247
20 Kim, I. S., Y. W. Choi, S. R. Lee, M. S. Lee, K. H. Huh, and S. Lee (2001) Removal and inactivation of hepatitis A virus during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. 39: 67-73
21 Boschetti, N., I. Niederhauser, C. Kempf, A. Stuhler, J. Lower, and J. Blumel (2004) Different susceptibility of B19 virus and mice minute virus to low pH treatment. Transfusion 44: 1079-1086   DOI   ScienceOn
22 International Conference on Harmonisation (1998) Guidance on viral safety evaluation of biotechnology products derived from cell lines of human or animal origin; availability. Fed. Regist. 63: 51074-51084
23 Kim, I. S., Y. W. Choi, S. R. Lee, H. S. Woo, and S. Lee (2001) Removal and inactivation of viruses during manufacture of a high purity antihemophilic factor VIII concentrate from human plasma. J. Microbiol. Biotechnol. 11: 497-503   과학기술학회마을
24 Roberts, P. L. and H. Hart (2000) Comparison of the inactivation of canine and bovine parvovirus by freezedrying and dry-heat treatment in two high purity factor VIII concentrates. Biologicals 28: 185-188   DOI   ScienceOn
25 Klein, H. G. (2005) Pathogen inactivation technology: cleansing the blood supply. J. Intern. Med. 257: 224-237   DOI   ScienceOn
26 Robertson, B. H. and D. D. Erdman (2000) Nonenveloped viruses transmitted by blood and blood products. Dev. Biol. Standard. 102: 29-35
27 Gummadi, S. N. (2003) What is the role of thermodynamics on protein stability? Biotechnol. Bioprocess Eng. 8: 9-18   DOI   ScienceOn
28 Kim, I. S., H. G. Eo, C. W. Park, C. E. Chang, and S. Lee (2001) Removal and inactivation of human immunodeficiency virus (HIV-1) by cold ethanol fractionation and pasteurization during the manufacture of albumin and immunoglobulins from human plasma. Biotechnol. Bioprocess Eng. 6: 25-30   DOI   ScienceOn
29 Berkman, S. A. (1988) Infectious complications of blood transfusion. Blood Rev. 2: 206-210   DOI   ScienceOn
30 Carpenter, J. F., M. J. Pikal, B. S. Chang, and T. W. Randolph (1997) Rational design of stable lyophilized protein formulations: some practical advice. Pharm. Res. 14: 969-975   DOI   ScienceOn